CEL-SCI Corporation (CEL-SCI) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 1997.
Business Overview: CEL-SCI is a biotechnology company focused on the research and development of drugs and vaccines. Its primary products include MULTIKINE (an immunotherapy "cocktail" for cancer) and HGP-30 (a synthetic peptide vaccine for AIDS). The company also acquired a T-cell Modulation Process (L.E.A.P.S.) in 1997. The company has no commercial product sales and relies on equity financing and investment income to fund operations.
Key Financial Metrics
| Metric | Fiscal 1997 | Fiscal 1996 | Fiscal 1995 |
|---|---|---|---|
| Total Revenues (Investment & Other) | $438,145 | $322,370 | $423,765 |
| Net Loss | $(8,189,458) | $(6,326,666) | $(3,878,638) |
| Loss Per Share | $(0.88) | $(0.98) | $(0.89) |
| Research & Development Expenses | $6,011,670 | $3,471,477 | $1,824,661 |
| Cash and Cash Equivalents | $3,508,606 | $3,549,810 | $3,886,950 |
| Working Capital | $4,581,247 | $10,266,104 | $3,983,699 |
| Total Liabilities | $508,617 | $294,048 | $1,516,978 |
Note: The company reported no operating revenue from product sales. Revenues consisted entirely of investment income and other minor sources.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 29% to $8.19 million in 1997 compared to $6.33 million in 1996. This was driven primarily by a 73% increase in Research and Development (R&D) expenses.
- R&D Expense Drivers: The surge in R&D costs included a $2.25 million charge for the purchase of MULTIKINE rights from Sittona Company and $125,000 for the acquisition of L.E.A.P.S. technology from Cell-Med. These were expensed immediately.
- Investment Portfolio: Investment securities available for sale decreased significantly from $6.5 million in 1996 to $745,000 in 1997 as the company liquidated assets to fund operations.
- Capital Structure: The company completed the conversion of all Series A, B, and C Preferred Stock into common stock during the fiscal year. In December 1997 (post-period), the company raised $10 million via Series D Preferred Stock.
Outlook, Risks, and Management Commentary
- Liquidity and Funding: The company expects to spend approximately $3.5 million on R&D and clinical trials in the coming year. Management states that substantial additional funds will be needed for extensive clinical trials required for FDA approval. Future operations depend on raising capital through securities sales or debt financing.
- Regulatory Risks: There is no assurance that regulatory approval will be obtained for MULTIKINE or HGP-30. Clinical trials conducted under state or foreign authority approvals may not be accepted by the FDA, potentially delaying commercialization for years.
- Related Party Transactions: The acquisition of MULTIKINE rights involved Sittona Company, B.V., which was previously owned by the company's President and Director, Maximilian de Clara. The transaction involved cash and stock issuance.
- Competition: The company faces intense competition from large pharmaceutical companies with greater resources developing genetically engineered IL-2 products and AIDS treatments.
Investor Verification Checklist
- Cash Burn Rate: Verify the company's ability to fund the projected $3.5 million R&D spend given the reduction in investment securities and the lack of operating revenue.
- Regulatory Pathway: Confirm the status of FDA acceptance for clinical trial data previously gathered under state or foreign approvals for MULTIKINE and HGP-30.
- Dilution Risk: Assess the impact of recent and potential future equity issuances (Series D Preferred Stock and warrants) on existing shareholder value.
- Related Party Dealings: Review the terms and valuation of the $2.25 million MULTIKINE rights acquisition from Sittona, given the historical ownership ties to the CEO.
- Manufacturing Dependency: Note that the company relies on a single third-party supplier for MULTIKINE production, with a 6-10 month lead time to secure an alternative source.